Bio Convention in China

BIO中国生物产业大会年度会议

PROGRAM

大会手册

October 24–25, 2012
Kerry Hotel, Pudong, Shanghai

2012年10月24日 至25日
上海浦东嘉里大酒店

Hosted by
主办方

Bio Biotechnology Industry Organization
全球生物技术工业组织

Co-hosted by
联合主办方

CCPIE 中国医药国际交流中心

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.

Published by

Biotechnology Industry Organization
1201 Maryland Ave., SW, Suite 900
Washington DC, 20024
202-962-9200 | www.bio.org

Biotechnology Industry Organization

James C. Greenwood, President and Chief Executive Officer

Emerging Companies and Business Development

Alan F. Eisenberg, Executive VP, Emerging Companies & Business Development

Joseph S. Dillon, CLP, Managing Director, Investor Relations & Business Development

Jennifer C. Welch, CMP, Managing Director, Meetings Operations & Marketing

Joe Colangelo, Director, Business Development

Celia Economides, MPH, Director, Investor Relations & Programs

David Thomas, CFA, Director, Industry Research & Analysis

John Atay, Manager, Budgeting & Operations

Bernadette Blake, Manager, Registration & Customer Service

Rena'e Love, Manager, Partnering Programs & Investor Outreach

Monika Nielsen, Manager, Event Logistics & Customer Service Operations

Sponsorship and Membership

Amy Finan, Vice President, Corporate Development & Marketing

Jason Rupp, Managing Director, Membership & Marketing

John Sloan, Managing Director, External Relations & Development

Elizabeth Gaskins, Director, Membership

Beth Perkins, Director, Sponsorship

Privacy

In accordance with its Privacy Policy, BIO does not sell or rent its customer information or usage data to third parties.

Biotechnology Industry Organization

全球生物技术工业组织

总部设于华盛顿的全球生物技术工业组织（BIO）作为世界上最大的生物技术组织，在世界范围内拥有超过1200多名会员。BIO会员的业务则遍及创新型医疗产品研发，以及创新型农业，工业，环境生物科技等各个领域的产品研究与开发。BIO以举办每年全球最大的业界盛会 – BIO国际生物产业大会闻名，并在世界各地举办由生物技术行界领先的创新者与投资商参与的合作会议。

出版单位

全球生物技术工业组织

美国华盛顿哥伦比亚特区

马里兰大道西南1201号900室

邮编20024

202-962-9200 | www.bio.org

全球生物技术产业组织（BIO）

James C. Greenwood，总裁兼首席执行官

新兴企业及商务拓展业务部

Alan F. Eisenberg，新兴企业及商务拓展，执行副总裁

Joseph S. Dillon，CLP，投资关系及商务拓展，总监

Jennifer C. Welch，CMP，会务运营及市场营销，总监

Joe Colangelo，商务拓展，主任

Celia Economides，MPH，投资关系及项目，主任

David Thomas，CFA，行业调研分析家

John Atay，预算与运营，经理

Bernadette Blake，注册及客户服务，经理

Rena'e Love，合作伙伴及投资人外展活动，经理

Monika Nielsen，后勤及客户服务运营，经理

赞助商及会员业务部

Amy Finan，企业发展与市场营销，副总裁

Jason Rupp，会籍管理与市场营销，总监

John Sloan，对外关系执行总监

Elizabeth Gaskins，会籍管理，主任

Beth Perkins，赞助业务，主任

隐私保护

BIO将根据隐私政策保护客户信息，不会对客户隐私进行出售与出租，或交由第三方使用。

ADVISORY COMMITTEE

George Baeder, Senior Vice President, Asia Pacific Consulting and China Commercial, Quintiles

Xue Baizhong, Chairman and Chief Executive Officer, Nuokang Biopharma

Helen Chen, Director & Partner, L.E.K. Consulting

Leon Chen, Founder and Managing Partner, Frontline BioVentures

Li Chen, President & CEO, Hua Medicine, China

Bill Guo, PhD, Chairman and Founder, Venturepharm Group

May-Kin Ho, PhD, Advisory Director, Goldman, Sachs & Co.

James Li, Vice President & General Manger, Greater China, Amgen China

Aihua Pan, PhD, MD, Chairman, SinoBioway Group

Rajesh Parekh, Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company

Yinxiang Wang, PhD, CEO and Chief Scientific Officer, Zhejiang Beta Pharma

Jerry Xiao, Vice General Manager, Corporate Technology Center, Fosun Pharma

Steve Yang, Vice President, Head of R&D, Asia and Emerging Markets, AstraZeneca, China

Tony Zhang, Vice President, Global External R&D, Asia, Eli Lilly and Company

Xu Zhang, Deputy President, Shanghai Branch, Chinese Academy of Sciences

咨询委员会

George Baeder，高级副总裁，亚太咨询和中国商业， 昆泰医药发展有限公司

薛百忠，董事长兼首席执行官，诺康生物制药

陈玮，负责人兼合作伙伴，艾意凯咨询公司

陈连勇，创始人和执行合伙人，通和资本

陈力，总裁兼首席执行官，华医药有限公司

郭夏，执行董事兼首席执行官，万全科技药业有限公司

何美坚，咨询总监，高盛投资集团

李怡平，大中华区副总裁兼总经理，安进（中国）

潘爱华，PhD，MD，董事长，北大未名生物工程集团

潘睿杰，亚洲制药和医药产品业务部主管，麦肯锡公司

王印祥博士，CEO兼首席科学家，浙江贝达药业

肖振宇，复星医药企业技术中心副总经理

杨青，亚洲及新兴市场副总裁及研发负责人，阿斯利康（中国）

张彦涛，全球外部研发亚洲副总裁，礼来制药

张旭，中科院上海分院副院长

SPONSORS

BIO thanks the following sponsors for their support.

CONFERENCE CO-HOST

CO-SPONSORS

中国医药企业管理协会
Chinese Pharmaceutical
Enterprises Association

上海市生物医药科技产业促进中心
Shanghai Center of Biomedicine Development

中国生物技术创新服务联盟
ALLIANCE OF BIO-BOX OUTSOURCING,CHINA

赞助商

BIO特此感谢以下赞助单位对本届活动的大力支持

联合主办方

大会协办方

中国医药企业管理协会
Chinese Pharmaceutical
Enterprises Association

上海市生物医药科技产业促进中心
Shanghai Center of Biomedicine Development

中国生物技术创新服务联盟
ALLIANCE OF BIO-BOX OUTSOURCING,CHINA

SPONSORS

BIO DOUBLE HELIX SPONSORS

Abbott
A Promise for Life

AMGEN

AstraZeneca

Baxter

biogen idec

HUMAN GENOME SCIENCES
A GSK company

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

MedImmune

SANOFI

BIO HELIX SPONSORS

gsk GlaxoSmithKline

Lilly

MSD

Roche

赞助商

白金级（DOUBLE HELIX）赞助商

Abbott
A Promise for Life

AMGEN

AstraZeneca

Baxter

biogen idec

HUMAN GENOME SCIENCES
A GSK company

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

MedImmune

SANOFI

黄金级（HELIX）赞助商

gsk GlaxoSmithKline

Lilly

MSD

Roche

Sponsors

Conference Sponsors

AMERICAN ELEMENTS

CMC 中国医药城 China Medical City

COVINGTON
COVINGTON & BURLING LLP

FLUOR

GLOBAL INTELLECTUAL PROPERTY CENTER

Lonza

新生源 NEW SUMMIT BIOPHARMA

Shook, Hardy & Bacon L.L.P.
www.shb.com

UPS
WE ♡ LOGISTICS™

Media Partners

Asia Monitor

BioCentury®

BioPharm Insight
An Infinata intelligence solution

CHINA HEALTHCARE INVESTMENT CONFERENCE

Elsevier BusinessIntelligence
Essential Insight for the Healthcare Industry

GBI

JAIC ASIABIO network

nature publishing group

npg

Bio Convention in China
BIO中国生物产业大会年度会议

赞助商

大会赞助商

AMERICAN ELEMENTS

CMC 中国医药城 China Medical City

COVINGTON
COVINGTON & BURLING LLP

FLUOR

GLOBAL INTELLECTUAL PROPERTY CENTER

Lonza

新生源 NEWSUMMIT BIOPHARMA

Shook, Hardy & Bacon L.L.P.
www.shb.com

ups
WE ♥ LOGISTICS™

媒体合作伙伴

Asia Monitor

BioCentury

BioPharm Insight
An Infinata intelligence solution

CHINA HEALTHCARE INVESTMENT CONFERENCE

Elsevier BusinessIntelligence
Essential Insight for the Healthcare Industry

GBI

JAIC ASIABIO network

nature publishing group

npg

Contents

Hosted by

Bio Biotechnology Industry Organization

Co-hosted by

CCPIE 中国医药国际交流中心

Bio Convention in China

BIO中国生物产业大会年度会议

内容

主办方

Biotechnology Industry Organization

全球生物技术工业组织

联合主办方

PROGRAM OVERVIEW

WEDNESDAY, OCTOBER 24, 2012

7:30 AM–8:30 AM	Networking Breakfast	*Pudong Ballroom*
8:30 AM–9:55 AM	One-on-One Partnering	*Grand Shanghai Ballroom 2 & 3*
8:30 AM–9:55 AM	Exhibits	*Grand Shanghai Ballroom 2 & 3*
8:30 AM–9:55 AM	Company Presentations	*Function Rooms 3 & 4*
8:30 AM–9:55 AM	**Globalization of Chinese Companies**	*Function Room 1*
	Biopharma Strategy 101: Biopharma's China Business Plan	*Function Room 2*
10:00 AM–12:30 PM	**Opening Ceremony & Keynote Session**	*Grand Shanghai Ballroom 1*

Welcoming Remarks:

- Hon. James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO)
- Zhao Yajun, Director General, China Council for Pharmaceutical International Exchange (CCPIE)
- Chinese National Center for Biological Development (CNCBD) Representative
- Xu Zuxin, Deputy Director General, Science and Technology Commission of Shanghai Municipal Government
- Luo Xielong, President, Renhe Group & Executive Vice President, Chinese Pharmaceutical Enterprise Association (CPEA)
- Wang Lanzhong, Vice Chairman of Shanghai Biopharmaceutics Industry Association (SBIA)
- Beijing Pharmaceutical and Biotech Center (BPBC) Representative
- Robert Griffiths, Consul General, Consulate General of the United States of America, Shanghai, China

Keynote Speakers:

- Sun Xianze, Deputy Commissioner, State Food and Drug Administration (SFDA)
- Governor Jon Huntsman, 9th United States Ambassador to China

12:30 PM–1:25 PM	Networking Lunch	*Pudong Ballroom*
1:30 PM–4:25 PM	One-on-One Partnering	*Grand Shanghai Ballroom 2 & 3*
1:30 PM–4:25 PM	Exhibits	*Grand Shanghai Ballroom 3 & 4*
1:30 PM–4:25 PM	Company Presentations	*Function Rooms 3 & 4*
1:30 PM–2:55 PM	**Achieving Success via Innovation in Biosimilars**	*Function Room 1*
	Small Companies Thinking Big: China Tactical Strategies	*Function Room 2*
3:30 PM–4:55 PM	**Comparative Legal Systems—US, China & Beyond**	*Function Room 1*
	Trends in Cancer Research and Oncology Treatment Development in China	*Function Room 2*
4:30 PM– 5:25 PM	**Industry Discussion: Building a World-Class Innovative Biologics Industry in China**	*Function Room 3*
	Trends in Investment and Cross-Border Development	*Function Room 4*
5:00 PM–5:45 PM	Buses depart for Gala Reception (last bus leaves at 5:45 PM)	*Hotel Main Lobby*
6:00 PM–9:00 PM	Gala Reception *Sponsored by Abbott*	*Dragon Boat River Cruise Shanghai No. 307 Wai Ma Road (near Zhongshan South Road & Fuxin East Road)*

会议议程总览

2012 年 10 月 24 日，星期三

7:30-8:30	交流早餐	*浦东宴会厅*
8:30-9:55	一对一合作伙伴	*大上海宴会厅2 & 3*
8:30-9:55	展览	*大上海宴会厅2 & 3*
8:30-9:55	公司展示	*功能厅 3 & 4*
8:30-9:55	中国企业走向世界	*功能厅 1*
	生物制药战略101：生物制药公司在华业务计划	*功能厅 2*
10:00-12:30	**开幕典礼及主题座谈会**	*大上海宴会厅1*

欢迎致辞：

- 尊敬的James C. Greenwood 先生，总裁兼首席执行官，全球生物技术工业组织 （BIO）
- 赵亚军，中国医药国际交流中心主任
- 中国生物技术发展中心代表
- 徐祖信，上海市政府科委副主任
- 骆燮龙，执行副总裁，仁和集团总裁和 CPEA
- 王兰忠，上海市生物医药行业协会副会长
- 北京生物技术和新医药产业促进中心代表 （BPBC）
- 葛瑞风，总领事，美国驻上海总领事馆

主题演讲嘉宾：

- 孙咸泽，国家食品药品监督管理局副局长
- 洪博培州长，前美国驻华大使

12:30-13:25	交流午餐	*浦东宴会厅*
13:30-16:25	一对一合作伙伴	*大上海宴会厅2 & 3*
13:30-16:25	展览	*大上海宴会厅3 & 4*
13:30-16:25	公司展示	*功能厅 3 & 4*
13:30-14:55	通过生物仿制药创新项目取得成功	*功能厅 1*
	小企业大思想：中国战术策略	*功能厅 2*
15:30-16:55	比较美国、中国以及它国的法律体系	*功能厅 1*
	中国的癌症研究和肿瘤治疗发展趋势	*功能厅 2*
16:30 - 17:25	行业讨论：打造世界一流的中国创新型生物制品企业	*功能厅3*
	投资及跨国发展的趋势	*功能厅4*
17:00 - 17:45	招待酒会班车（末班车于下午5：45分启程）	*酒店大堂*
18:00-21:00	招待酒会	*浦江龙船游览*

赞助单位： 雅培

浦江龙船游览的地址是上海外马路307号（近中山南路复兴东路）。

PROGRAM OVERVIEW

THURSDAY, OCTOBER 25, 2012

7:30 AM–8:30 AM	Networking Breakfast	*Pudong Ballroom*
8:30 AM–9:55 AM	One-on-One Partnering	*Grand Shanghai Ballroom 2 & 3*
8:30 AM–9:55 AM	Company Presentations	*Function Room 3 & 4*
8:30 AM–9:55 AM	Exhibits	*Grand Shanghai Ballroom 2 & 3*
8:30 AM–9:55 AM	**Leadership Models in Translating Innovative Sciences**	*Function Room 1*
	Adapting to China's Changing Health Care System—Reimbursement, Health Care Reform & Affordability	*Function Room 2*
10:00 AM–11:25 AM	**Keynote Session** *Moderator:* • Perry A. Karsen, Chief Operations Officer & Executive Vice President, Celgene Corporation *Keynote Speakers:* • Peng Wang, PhD, Chief Scientific Officer, Simcere • Michael Rosenblatt, MD, Executive Vice President & Chief Medical Officer, Merck/MSD	*Grand Shanghai Ballroom 1*
11:30 AM–12:25 PM	Networking Lunch	*Pudong Ballroom*
12:30 PM–3:25 PM	One-on-One Partnering	*Grand Shanghai Ballroom 2 & 3*
12:30 PM–3:25 PM	Company Presentations	*Function Room 3 & 4*
12:30 PM–3:25 PM	Exhibits	*Grand Shanghai Ballroom 2 & 3*
12:30 PM–1:55 PM	**Development Trends (Part 1)—New Models of Cross Border R&D Structures**	*Function Room 1*
	Regulatory Review Process of New Medicines in China	*Function Room 2*
2:00 PM–3:25 PM	**Development Trends (Part 2)—New Models of R&D Structures in China**	*Function Room 1*
	Globalizing Traditional Chinese Medicines	*Function Room 2*
3:30 PM – 4:30 PM	Closing Reception	*Grand Shanghai Ballroom Foyer*

Schedule subject to change.

会议议程总览

2012 年 10 月 25 日，星期四

7:30-8:30	交流早餐	*浦东宴会厅*
8:30-9:55	一对一合作伙伴	*大上海宴会厅2 & 3*
8:30-9:55	公司展示	*功能厅 Room 3 & 4*
8:30-9:55	展览	*大上海宴会厅2 & 3*
8:30-9:55	创新型转化医学的领导层模式	*功能厅1*
	适应中国不断变化的医疗保健体系—医疗报销、医疗保健改革和负担能力	*功能厅2*
10:00-11:25	主题报告 *主持人：* • Perry A. Karsen, Celgene 公司，执行副总裁兼首席营运官 *主题演讲嘉宾：* • 王鹏博士，先声药业集团副总裁兼首席科学官 • Michael Rosenblatt，执行副总裁兼首席医务官，默克/默沙东	*大上海宴会厅1*
11:30-12:25	交流午餐	*浦东宴会厅*
12:30-15:25	一对一合作伙伴	*大上海宴会厅2 & 3*
12:30-15:25	公司展示	*功能厅3 & 4*
12:30-15:25	展览	*大上海宴会厅2 & 3*
12:30-13:55	发展趋势（第 1 部分）— 跨国研发结构的新模式	*功能厅1*
	中国新药监管审核流程	*功能厅2*
14:00-15:25	传统中医药走向世界	*功能厅1*
	发展趋势（第 2 部分）— 中国研发结构的新模式	*功能厅2*
15:30-16:30	闭幕招待会	*大上海宴会厅前厅*

本议程得视实际情况随时修正。

WEDNESDAY, OCTOBER 24, 2012
8:30 AM–9:55 AM
FUNCTION ROOM 1

Recommended for Chinese Attendees

Globalization of Chinese Companies

This panel will explore the globalization of Chinese companies, starting with the nuances of conducting business with Western biopharma companies and how to go about selling products outside of China. How can Chinese companies find local partners in new territories? What kinds of deal models are most prevalent in the West? Case studies showcasing strong, successful collaborations will provide strategic insight for Chinese companies eager to sell products beyond China's borders.

MODERATOR:

- Luo Xielong, President, Renhe Group & Executive Vice President, CPEA

PANELISTS:

- Lily Han, PhD, Deputy General Manager of International Development, Fosun Pharma
- May-Kin Ho, PhD, Advisory Director, Goldman, Sachs & Co.
- Sammy Jiang, Associate President, Luye Pharma Group Ltd.

WEDNESDAY, OCTOBER 24, 2012
8:30 AM–9:55 AM
FUNCTION ROOM 2

Recommended for Western Attendees

Biopharma Strategy 101: Biopharma's China Business Plan

Large biotech companies have shown a great interest in China, but have a short history in the country and limited ground operations. How should a Western biotech go about establishing a presence in China? Which operational strategies will allow them to get their innovative therapies into the hands of Chinese patients? A panel of biotech industry experts "trying to figure it out" will share their insights.

MODERATOR:

- Rajesh Parekh, Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company

PANELISTS:

- Boon Heon Tan, Managing Director, Biogen Idec, China
- Alec Reynolds, Commercial Director, Celgene China

2012 年 10 月 24 日，星期三
8:30 – 9:55
功能厅 1

推荐中方与会者参与

中国企业走向世界

本次研讨会将探讨中国企业的全球化趋势，深入分析与西方生物制药公司开展业务的细微差别，并探索中国企业如何使药品走出国门，进军世界。中国公司如何在新的地区寻找当地合作伙伴？西方企业最常采用的交易模式是什么？案例研究表明，建立紧密、成功的合作关系有助于中国企业获得战略性视角，并成功地将产品推向国外。

主持人：

- 骆燮龙，执行副总裁，仁和集团总裁和 CPEA

专家组成员：

- 韩厉玲，复星医药国际部副总经理
- 何美坚，咨询总监，高盛投资集团
- **姜**华，副总裁，绿叶制药集团有限公司

2012 年 10 月 24 日，星期三
8:30 – 9:55
功能厅 2

推荐西方与会者参与

生物制药战略 101：生物制药巨头的在华业务计划

大型生物技术公司早已瞄上中国这片市场，但是其在华投资历史并不长，缺乏实际运营经验。西方生物技术企业如何站稳中国市场？他们应采取哪些运营策略，才能使自己的创新性疗法被中国患者接纳？多位“专心钻研”的生物技术行业专家将发表各自的真知灼见。

主持人：

- 潘睿杰，亚洲制药和医药产品业务部主管，麦肯锡公司

专家组成员：

- 陈文雄，（中国）管理总监，百见艾迪
- Alec Reynolds，商务总监，Celgene（中国）公司

Opening Ceremony

WELCOMING REMARKS:

- Hon. James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO)
- Zhao Yajun, Director General, China Council for Pharmaceutical International Exchange (CCPIE)
- Chinese National Center for Biological Development (CNCBD) Representative
- Xu Zuxin, Deputy Director General, Science and Technology Commission of Shanghai Municipal Government
- Luo Xielong, President, Renhe Group & Executive Vice President, Chinese Pharmaceutical Enterprise Association (CPEA)
- Wang Lanzhong, Vice Chairman of Shanghai Biopharmaceutics Industry Association (SBIA)
- Beijing Pharmaceutical and Biotech Center (BPBC) Representative
- Robert Griffiths, Consul General, Consulate General of the United States of America, Shanghai, China

Keynote Session

SPEAKER:

- Sun Xianze, Deputy Commissioner, State Food and Drug Administration (SFDA)
- Governor Jon Huntsman, 9th United States Ambassador to China

开幕式

欢迎致辞：

- 尊敬的James C. Greenwood 先生，总裁兼首席执行官，全球生物技术工业组织 （BIO）
- 赵亚军，中国医药国际交流中心主任
- 中国生物技术发展中心代表
- 徐祖信，上海市政府科委副主任
- 骆燮龙，执行副总裁，仁和集团总裁和 CPEA
- 王兰忠，上海市生物医药行业协会副会长
- 北京生物技术和新医药产业促进中心代表 (BPBC)
- 葛瑞风，总领事，美国驻上海总领事馆

主题座谈会

演讲嘉宾:

- 孙咸泽，国家食品药品监督管理局副局长
- 洪博培州长，前美国驻华大使

WEDNESDAY, OCTOBER 24, 2012
1:30 PM–2:55 PM
FUNCTION ROOM 1

Recommended for Chinese Attendees

Achieving Success via Innovation in Biosimilars

Leading companies that have achieved global success in generic drug development, biosimilars and manufacturing will lend their insights on an intriguing panel discussion. What lessons can Chinese companies learn from their stories? How can Chinese companies use business and clinical strategies to position themselves for global success in this growing market?

MODERATOR:

- Alan Morrison, Vice President, Regulatory Affairs, Amgen

PANELISTS:

- Robert Chen, Sr. Director, Head of Business Development, Genor Biopharma
- H. Fai Poon, PhD, Director, Research & Development, Hisun Pharmaceutical
- Scott Liu, CEO & Co-Founder, Henlius Biopharmaceuticals, Inc.
- John Zhaolong Gong, PhD, MD, Chief Executive Officer, BL Pharmaceuticals

WEDNESDAY, OCTOBER 24, 2012
1:30 PM–2:55 PM
FUNCTION ROOM 2

Recommended for Western Attendees

Small Companies Thinking Big: China Tactical Strategies

Emerging and mid-sized biotech companies are exploring ways to enter China's lucrative market and maximize their investment in the country. With more limited resources than multinational biopharma companies, how can these smaller companies operate efficiently and give Chinese patients access to their innovative products? Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China.

MODERATOR:

- Jimmy Zhang, Greater China Lead, Licensing, Acquisitions & External Research, Worldwide Licensing & Acquisitions, Merck/MSD

PANELISTS:

- Friedhelm Blobel, PhD, President & Chief Executive Officer, SciClone Pharmaceuticals, Inc.
- Lian Yong (Leon) Chen, PhD, Founder & Managing Partner Frontline BioVentures
- Stanley C. Erck, President & Chief Executive Officer, Novavax, Inc.
- Kewen Jin, Managing Director, Nimbus Innoworks

2012 年 10 月 24 日，星期三
13:30-14:55
功能厅 1

推荐中方与会者参与

通过生物仿制药创新项目取得成功

在仿制药研发、生物仿制药和生产方面取得全球性成功的领先企业将在研讨会期间各抒己见，展开热烈讨论。中国企业可从他们的成功案例中汲取哪些经验？中国企业如何采用业务和临床战略，在这一快速发展的全球市场中占据一席之地？

主持人:

- Alan Morrison，副总裁，安进

专家组成员:

- 陈如雷，战略合作高级总监，嘉和生物药业有限公司
- 潘洪辉博士博士，研发总监，海正药业
- 刘世高，CEO 及共同创始人，汉霖生物制药公司
- 龚兆龙博士，总裁兼首席执行官，北京莱博赛路森药物科技有限公司

2012 年 10 月 24 日，星期三
13:30-14:55
功能厅 2

推荐西方与会者参与

小企业大思想：中国战术策略

新兴和中型生物技术公司都在积极探索中国这片利润丰厚的市场，并极力扩大在中国的投资。与跨国生物制药公司相比，这些规模较小的公司资源有限，如何才能有效运作，让中国患者获得他们的创新产品呢？让业内专家和生物技术管理人员来出谋划策，帮助小企业解决这个棘手的业务策略问题吧。

主持人:

- Jimmy Zhang，全球授权与收购大中国区负责人，默克/默沙东

专家组成员:

- Friedhelm Blobel，总裁兼首席执行官，赛生制药公司
- 陈连勇博士，创始管理合伙人，通和资本
- Stanley C. Erck，总裁兼首席执行官，Novavax有限公司
- 金克文博士，董事、总经理，齐云创智工坊

WEDNESDAY, OCTOBER 24, 2012
3:30 PM–4:55 PM
FUNCTION ROOM 1

Recommended for Chinese Attendees

Comparative Legal Systems—US, China & Beyond

Learn how to navigate the complexities of the European and US regulatory landscapes. What are the barriers to entry in these markets and how can companies gain market access? Regulatory and legal experts will explore the similarities & differences between the US, Chinese & European regulatory systems.

MODERATOR:

- TBD

PANELISTS:

- Jasemine C. Chambers, PhD, JD, Deputy Administrator for External Affairs, United States Patent & Trademark Office (USPTO)
- Gang Wang, PhD, Assistant Country Director, China Office, US Food and Drug Administration (US FDA)
- Yang Wei, Deputy Director General, SFDA Drug Registration Department

WEDNESDAY, OCTOBER 24, 2012
3:30 PM–4:55 PM
FUNCTION ROOM 2

Recommended for All Attendees

Trends in Cancer Research and Oncology Treatment Development in China

Cancer is the leading cause of death in China, and novel oncology treatments are critical to preserving the nation's public health. This panel will discuss trends in Chinese cancer research and survey the novel oncology drug R&D pipeline for China.

MODERATOR:

- Richard Yeh, Head, China Healthcare Research, Citi Investment Research

PANELISTS:

- Guoqing Cao, PhD, Vice President, Global Head of Discovery Biology Division, Hengrui Pharmaceutical R&D, Hengrui Pharmaceuticals
- Yinxiang Wang, PhD, CEO & Chief Scientist, Zhejiang BetaPharma Co., Ltd.
- Jinzi J. Wu, PhD, Co-Founder, President, & CEO, Ascletis Inc.

2012 年 10 月 24 日，星期三
15:30-16:55
功能厅 1

推荐中方与会者参与

比较美国、中国及它国的法律体系

学习如何应对欧洲和美国监管环境的复杂情形。进军这些市场会面临哪些障碍，企业如何获得市场准入许可？监管和法律专家将探讨美国、中国和欧洲监管体系之间的异同。

主持人:

- 待定

专家组成员:

- Jasemine C. Chambers博士，对外事务副署长，美国专利商标局（USPTO）
- 王刚，助理主任，美国FDA驻华办公室
- 杨威,副司长,国家食品药品监督管理局（SFDA）药品注册司

2012 年 10 月 24 日，星期三
15:30-16:55
功能厅 2

推荐所有与会者参与

中国的癌症研究和肿瘤治疗发展趋势

癌症是导致中国人死亡的首要原因，因此，创新型肿瘤疗法成为确保中国民众健康的关键手段。本次研讨会将讨论中国癌症研究趋势，并对中国创新型肿瘤药物研发渠道展开调查。

主持人:

- Richard Yeh，亚太地区医疗主管,花旗投资调研

专家组成员:

- 曹国庆博士，全球研发生物副总裁，恒瑞医药股份有限公司
- 王印祥博士，CEO兼首席科学家，浙江贝达药业有限公司
- 吴劲梓博士，创始人和首席执行官，世方药业（杭州）有限公司

WEDNESDAY, OCTOBER 24, 2012
4:30 PM–5:25 PM
FUNCTION ROOM 3

Recommended for All Attendees

Industry Discussion: Building a World-Class Innovative Biologics Industry in China

The R&D based Pharmaceutical Association Committee (RDPAC) and BIO have commissioned a study with the support of the Boston Consulting Group (BCG) to assess multiple policy levers which have the potential to accelerate the development of the therapeutic biologics sector in China and the integration of the Chinese therapeutic biologics industry into global R&D and healthcare markets. The therapeutic biologics industry holds significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in diseases such as diabetes, cancer, and immunological impairment. As biotechnology has been designated as one of China's seven strategic emerging industries by the government in the current 12th five-year plan, this study is in the process of formulating a set of recommendations which balance the immediate next steps for the industry with long-term action plans.

MODERATOR:

- Joseph Damond, Senior Vice President, International Affairs, Biotechnology (BIO)

PANELISTS:

- James Cai, Medical Director, Shanghai Roche Pharmaceuticals Ltd.
- Joseph Cho, Managing Director, RDPAC
- Luwen Shi, PhD, Professor, Chairman, Peking University (PKU), Department .of Pharmacy Administration & Clinical Pharmacy
- Yu Mingde, President, China Pharmaceutical Enterprises Association

WEDNESDAY, OCTOBER 24, 2012
4:30 PM–5:25 PM
FUNCTION ROOM 4

Recommended for All Attendees

Trends in Investment and Cross-Border Development

China is actively investing in biotechnology development through many different avenues. Hear a panel of experts explain the advantages of operating in China and engaging in cross-border collaborations, and learn how Chinese and Western biopharma companies can gain access to meaningful capital.

MODERATOR:

- Sun Wansong, PhD, Director of Investment Promotion, Ministry of Commerce, People's Republic of China

PANELISTS:

- Samantha Du, PhD, Managing Director, Sequoia Capital
- Alan Hu, Healthcare Fund Partner, Deloitte
- Yu Yangfei, Section Chief, Fudding Construction Section of Bio City of Wu Han Guang Gu Cluster
- Wu Yue, Director, Management Committee, Taizhou National Medical Hi-tech Development Zone

2012 年 10 月 24 日，星期三
16:30-17:25
功能厅 3

推荐所有与会者参与

行业讨论：打造世界一流的中国创新型生物制品企业

中国外商投资企业协会药品研制和开发行业委员会 (RDPAC)及全球生物技术工业组织委托波士顿咨询集团（BCG）对多项有潜在加速中国治疗用生物制品行业发展，并使其与全球研发和医疗保健市场融为一体方面的政策杠杆所起到的作用进行评估。治疗用生物制品行业的发展对中国生物产业实现突破性创新，攻克包括糖尿病、癌症、免疫受损疾病等在内的医疗难题具有深远意义。 生物科技产业已经作为中国七大战略性新兴产业之一被列入国家“十二五”规划，此项评估对于制定行业的近期走向以及远景规划的一套方案会起到作用。

主持人:

- Joseph Damond，国际事务部高级副总裁，全球生物技术产业组织（BIO）

专家组成员:

- James Cai，医学总监，上海罗氏制药有限公司
- 卓永清，执行总裁，中国外商投资企业协会药品研制和开发行业委员会(RDPAC)
- 史录文，教授，主任，北京大学，药学院药事管理与临床药学系
- 于明德，中国医药企业管理协会会长

2012 年 10 月 24 日，星期三
16:30-17:25
功能厅 4

推荐所有与会者参与

投资及跨国发展的趋势

中国正在积极的通过多方渠道对生物科技发展进行投资。聆听行业专家深入探讨在中国运营和开展跨境合作的优势，了解中西方制药企业应该如何有效的吸引投资、赢得资本青睐。

主持人:

- 孙万松，商务部投资促进事务局中心项目运营部主任

专家组成员:

- 杜莹，中国基金董事总经理， 红杉资本
- Alan Hu， 合伙人，德勤康健护理基金
- 喻艳飞，财务融资负责人，武汉光谷生物城 建设融资处
- 吴跃，泰州医药高新技术产业开发区管理委员会 主任

THURSDAY, OCTOBER 25, 2012
8:30 AM–9:55 AM
FUNCTION ROOM 1

Recommended for All Attendees

Leadership Models in Translating Innovative Sciences

How are Chinese clinicians, researchers, hospital healthcare officials, academia and government agencies incorporating translational medicine into the research process and practice? What agencies and institutions are at the forefront of this effort, and which areas of medicine are likely to benefit first? This panel will provide an overview of China's translational medicine landscape and highlight US and European programs that could serve as strong models for China.

MODERATOR:

- Li Qing, Director, Medicines Science and Technology Development Center, Ministry of Health

PANELISTS:

- Bai Chunxue, PhD, Professor of Medicine and Chief of Pulmonary Medicine, Zhongshan Hospital, Fudan University
- Jennifer Hu, PhD, VP and Head of Innovation Center China, Global Drug Discovery, Bayer Healthcare
- Duan Junguo, Director, National TCM Clinical Experiment Research Center (Chengdu) Vice-Director, Affiliated Hospital, Chengdu University of TCM
- Katherine Ku, Director, Office of Technology Licensing, Stanford University

THURSDAY, OCTOBER 25, 2012
8:30 AM–9:55 AM
FUNCTION ROOM 2

Recommended for Western Attendees

Adapting to China's Changing Health Care System—Reimbursement, Health Care Reform & Affordability

Affordability is a central focus of China's healthcare reforms. What changes in healthcare reform and the private payor markets might occur that can assist with affordability and access? Will new medicines become affordable in China, and can new technologies and developments help create less expensive medicines? What does the looming expansion of the Essential Drug List and National Reimbursement Drug List mean for both Chinese and Western companies? Experts and representatives from the Chinese Government will tackle reimbursement, healthcare reform and private insurance issues.

MODERATOR:

- George Baeder, Senior Vice President, Asia Pacific Consulting and China Commercial, Quintiles

PANELISTS:

- Joseph Cho, Managing Director, R&D-based Pharmaceutical Association Committee (RDPAC)
- John V. Oyler, Founder & CEO, BeiGene
- Qiao Shanbo, General Manager, PICC Health Shanghai
- Harald Sprenger, Director, Market Access Strategy & Private Insurance, Roche

2012 年 10 月 25 日，星期四
8:30-9:55
功能厅 1

推荐所有与会者参与

创新型转化医学的领导层模式

中国临床医生、研究人员、医院医疗保健官员、学术机构和政府机构如何将转化医学融入研发流程和执业实践中？哪些机构处于这一领域的前沿，哪些药物将首先获益？本次研讨会将概述中国转化医学的现状，并重点探讨中国可以借鉴哪些成功的美国和欧洲项目。

主持人：

- 李青，卫生部医药卫生科技发展研究中心主任

专家组成员：

- 白春雪，教授及呼吸科主任，复旦大学附属中山医院
- Jennifer Hu，副总裁兼中国创新中心负责人，拜耳医药保健全球药物研发
- 段俊国，成都中医药大学临床医学院党委书记
- Katherine Ku，斯坦福大学技术许可办公室主任

2012 年 10 月 25 日，星期四
8:30-9:55
功能厅 2

推荐西方与会者参与

适应中国不断变化的医疗保健体系—医疗报销、医疗保健改革和负担能力

普通大众的医疗负担能力是中国医改的核心所在。医改和商业保险市场中的哪些变革会有助于解决看病难和看病贵的问题？中国的新药价格公众负担得起吗，新技术和新发展能帮助降低药物费用吗？即将出台的《基本药物目录》和《国家医保药品目录》扩展版将对中国企业和西方企业产生哪些影响？中国政府专家和代表将着手解决医保报销、医疗改革和商业保险问题。

主持人：

- George Baeder，高级副总裁，亚太咨询和中国商业， 昆泰医药发展有限公司

专家组成员：

- 卓永清，执行总裁，中国外商投资企业协会药品研制和开发行业委员会
- 欧雷强（John V. Oyler），创始人及首席执行官，百济神州科技有限公司
- 乔善波，总经理,中国人民健康保险股份有限公司上海分公司
- Harald Sprenger，主任，市场进入战略与私人保险， 罗氏

Recommended for All Attendees

Keynote Session

The recent joint venture between Merck and Simcere has drawn international attention and could serve as a model for future collaborations between Chinese and Western companies. The Chief Scientific Officers from both companies will discuss the venture and how both companies are addressing the unmet medical needs of China's populace.

MODERATOR:

- Perry A. Karsen, Chief Operations Officer & Executive Vice President, Celgene Corporation

SPEAKERS:

- Peng Wang, PhD, Chief Scientific Officer, Simcere
- Michael Rosenblatt, MD, Executive Vice President & Chief Medical Officer, Merck/MSD

Who's Who *Speaker listings and biographies are in order of appearance.*

Peng Wang, PhD – Chief Scientific Officer, Simcere

Dr. Peng Wang, a member of the China National "1000-Talents Program", is currently Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; "SCR" at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech (wuxiapptec.com; "WX" at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Prior to joining WuXi PharmaTech, Dr. Wang worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to discovery and early development of 16 drug candidates in US and China, and to establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his PhD in Biochemistry from the University of Tokyo, and his BS in Medicinal Chemistry from the China Pharmaceutical University.

Perry Karsen– Executive Vice President, Chief Operations Officer, Celgene Corporation

Perry Karsen is an Executive Vice President and currently serves as Chief Operations Officer at Celgene Corporation. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company, from February 2009 until July 2010. Previously, Mr. Karsen was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region. Mr. Karsen served as Senior Vice President, Business Development at Human Genome Sciences; and earlier in his career, held positions including Vice President, Strategic Business Analysis and Development, Bristol-Myers Squibb; Senior Vice President Marketing and Sales, Zimmer, Inc.; Director, Business Development and Representative Director, Japan, at Genentech; and various domestic and international roles with Abbott Laboratories. Additionally, Mr. Karsen was a General Partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices.

Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO), the world's largest biotechnology industry organization; a member of the Board of Directors of BayBio, representing the biotechnology industry in the San Francisco Bay Area; and a member of the Board of Directors for the Life Sciences Foundation, an organization dedicated to telling the story of biotechnology. In addition, Mr. Karsen is a member of the Board of Directors of Agios Pharmaceuticals, a private biotechnology company pioneering research in cancer metabolism.

Mr. Karsen has a Masters of Management degree from Northwestern University's Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a BS in Biological Sciences from the University of Illinois, Urbana.

推荐所有与会者参与

主题报告

默克公司与先声药业近期签署的合作协议引起了广泛的国际关注，同时也可作为未来中西方企业合作的模式。双方公司的首席科学官将对本次合作进行深入探讨，并就如何满足中国百姓的医疗保健需求各抒己见。

主持人:

- Perry A. Karsen，执行副总裁兼首席营运官， Celgene公司

演讲嘉宾:

- 王鹏博士，先声药业集团副总裁兼首席科学官
- Michael Rosenblatt,执行副总裁兼首席医务官，默克/默沙东

名人录 *演讲嘉宾及简历（按出场先后排序）*

王鹏博士 – 先声药业集团副总裁兼首席科学官

2008-2009王鹏博士是“千人计划”国家特聘专家，江苏省“双创”领军人才，美国药物信息协会（DIA)中国区顾问，担任中国药理学会药物毒理专业委员会，神经药理专业委员会，中国药学会应用药理学会，中国毒理学和药物毒理与安全性评价专业委员会等多个专业委员会委员，是目前北美华人最大的制药/生物技术专业协会-美中医药开发协会（SAPA）创始人之一。在加入无锡药明康德之前，王博士曾在美国新泽西州的先灵葆雅公司从事研发到早期临床开发工作 18 年。王博士为美国和中国的候选药物研发和早期16开发做出了卓越贡献，并促成了先声药业与几家美国公司之间的合作伙伴关系。王博士作为通讯作者，在诸多领 先的科学期刊上发表了多篇论文，其中包括 Proc.Natl.Acad.Sci. USA、J. Biol.Chem.、Blood、J.Immunol.、Am. J. Respir.Crit.Care Med.、Mol. Pharmacol.、Biochem.J. 等。王博士在东京大学获得了生物化学博士学位，在中国药科大学获得了药物化学理学学士学位。

Perry A. Karsen – Celgene 公司，执行副总裁兼首席营运官

Perry Karsen目前是 Celgene公司的执行副总裁兼首席营运官。此前，在2009年2月至2010年7月期间，他曾在生物技术公司Pearl Therapeutics担任总裁兼首席执行官。Karsen先生早先还曾在Celgene担任高级副总裁、全球商务拓展负责人，并作为亚太区总裁负责新兴业务。

Perry也曾在Human Genome Sciences担任商务拓展高级副总裁。此外，他还出任过Bristol-Myers Squibb公司战略业务分析与发展副总裁、 Zimmer公司营销及销售高级副总裁、以及Genentech日本商务拓展代表董事，并在雅培制药担任过多项国际与国内职位。他还曾是Pequot Ventures 的合伙人之一，负责生物技术与医疗器械早期及晚期投资项目。

Karsen先生目前也是世界上最大的生物技术组织—美国全球生物技术产业组织（BIO）、以及旧金山Bay 地区生物科技产业代表机构—BayBio的董事会成员之一。此外，他还是生命科学基金（Life Sciences Foundation）、以及在肿瘤代谢研究领域领先的生物科技企业—Agios Pharmaceuticals的董事会成员。

Karsen先生拥有美国西北大学凯洛格管理学院硕士学位、及杜克大学生物教育硕士学位，并在美国伊利诺伊大学获得了生物科学学士学位。

Michael Rosenblatt, MD – Executive Vice President and Chief Medical Officer, Merck/MSD

Scientist, educator, hospital and global healthcare company executive, Michael Rosenblatt, MD, is Executive Vice President And Chief Medical Officer at Merck. He is the company's primary external advocate on medical issues and represents the voice of the patient inside Merck.

Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School; and President of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and Senior Vice President for academic programs at BIDMC. He was also Director of the Harvard-MIT Division of Health Sciences and Technology.

Prior to these leadership positions, he was Senior Vice President for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.

Committed to innovation, he has served on the Board of Directors and Scientific Advisory Boards of several biotechnology companies and is a Scientific Founder of ProScript, Radius Pharmaceuticals and Theracrine.

Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the President of the American Society of Bone and Mineral Research.He received his undergraduate degree summa cum laude from Columbia University and his MD magna cum laude from Harvard Medical School.

Michael Rosenblatt – 执行副总裁兼首席医务官,默克/默沙东

医学博士迈克尔·罗森布拉特是一名科学家、教育家和医院与全球医疗企业的高管，目前担任默克公司执行副总裁和首席医疗官。他是默克关于医疗问题的主要发言人，代表着默克内部的广大患者。

罗森布拉特医生曾经担任过塔夫茨大学医学院院长，哈佛医学院乔治·迈诺特医学教授和贝丝以色列迪肯尼斯医疗中心（BIDMC）的总裁。他曾担任哈佛大学的学院院长，以及BIDMC 学术计划的高级副总裁。他还担任过哈佛-麻省理工卫生科学与技术部的主管。

在担任这些领导职位之前，他曾经是默克研发中心的高级副总裁，也是阿仑膦酸钠（FOSAMAX®）世界研发团队的领导人之一。早期，他担任过马萨诸塞州总医院内分泌科的主任。

他非常热衷于创新，曾在多个生物技术公司的董事会和科学咨询委员会中任职，并且是 ProScript、Radius Pharmaceuticals 和 Theracrine 的科技创办人。

罗森布拉特医生是美国临床调查学会和美国医师协会成员，美国科学进步协会成员以及

美国医师学院成员。还担任过美国骨骼与矿物质研究学会的主席。

他本科以优异的成绩毕业于哥伦比亚大学，于哈佛医学院取得医学博士学位，并获得优等生称号。

THURSDAY, OCTOBER 25, 2012
12:30 PM–1:55 PM
FUNCTION ROOM 1

Recommended for All Attendees

Development Trends (Part 1)—New Models of Cross-Border R&D Structures

There has recently been a flurry of drug development deals between multinational companies and Chinese biopharma companies. Which new models of R&D are being pursued? How does the co-development of biosimilars and new, innovative medicines fit into these research paradigms? How do industry-academic partnerships fit into the R&D model? Industry and academic research leaders will explore examples of successful cross-border drug development collaborations.

MODERATOR:

- Steve Yang, Vice President, Head of R&D, Asia and Emerging Markets, AstraZeneca, China

PANELISTS:

- Ralf Altmeyer, PhD, Director General, Institut Pasteur Shanghai
- Alan Gordon Lamont, Senior Director, Global External R&D, Regional Head ACEJ and Emerging Markets, Eli Lilly
- Joe McCracken, Global Head of Business Development, Roche

THURSDAY, OCTOBER 25, 2012
12:30 PM–1:55 PM
FUNCTION ROOM 2

Recommended for All Attendees

Regulatory Review Process of New Medicines in China

The rapid development of the Chinese pharmaceutical industry is presenting new opportunities for new medicine commercialization. Positive steps have been made towards drug registration standardization and the necessary levels of administrative investment. How can both Western and Chinese companies take advantage of China's review process to create mutually beneficial outcomes for patients and industry? How can the SFDA communicate with companies to improve the review process?

MODERATOR:

- Shaoyu Chen, Partner, Covington & Burling LLP

PANELISTS:

- Wassim Nashabeh, PhD, Global Head, Technical Regulatory Policy & Strategy, Genentech, Inc.
- Romi Singh, Executive Director, Global Regulatory Affairs & Safety, Amgen
- Tracy Wang, Regulatory Affairs China, Merck/MSD
- Chang Weihong, Division Chief, SFDA Drug Registration Department

2012 年 10 月 25 日，星期四
12:30-13:55
功能厅 1

推荐所有与会者参与

发展趋势（第 1 部分）— 跨国研发结构的新模式

近期，跨国企业和中国生物制药企业之间掀起药物开发合作狂潮。涌现出哪些新的研发模式？生物仿制药和创新型药物的联合开发方案如何融入这些研发模式中？行业与学术机构的合作关系如何适应这一研发模式？行业和学术研究机构领导者将探讨跨国药物研发合作的成功案例。

主持人：

- 杨青，亚洲及新兴市场副总裁及研发负责人，阿斯利康（中国）

专家组成员：

- Ralf Altmeyer，PhD，上海巴斯德研究所总干事
- Alan Gordon Lamont，全球对外研发资深总监，ACEJ及新兴市场区域主管，礼来
- Joe McCracken，商业拓展全球负责人，罗氏

2012 年 10 月 25 日，星期四
12:30-13:55
功能厅 2

推荐所有与会者参与

中国新药监管审核流程

中国制药企业正在飞速发展，这为新药的商业推广带来了新的机遇。中国政府针对药物注册和标准化以及管理投资的必要级别制定了积极的政策。中西方企业如何利用中国的审核流程，实现患者和行业的双赢局面？中国国家食品药品监督管理局如何与企业沟通，以改进审核流程？

主持人：

- 陈少羽，合伙人，科文顿·柏灵律师事务所

专家组成员：

- Wassim Nashabeh，博士，技术监管政策与执行策略，全球负责人，美国基因泰克公司
- Romi Singh，全球监管与安全事务执行总监，安进公司
- Tracy Wang，中国政策监管事务， 默克/默沙东
- 常卫红，副处长，国家食品药品监督管理局（SFDA）注册司生物制品处

THURSDAY, OCTOBER 25, 2012
2:00 PM–3:25 PM
FUNCTION ROOM 1

Recommended for All Attendees

Development Trends (Part 2)—New Models of R&D Structures in China

Backed by the government's strong commitment to promoting innovation in the biotech sector, new R&D structures in China have emerged in recent years. CRO's have begun to move beyond their traditional service space and have launched their own drug development platforms, while domestic academic-industry collaborations continue to flourish. Chinese biotech companies are also looking closer to home for their next partner to foster an innovative drug development pipeline. This panel will discuss how the country's focus on biotech innovation has spurred new models of R&D structures for Chinese companies.

MODERATOR:

- Jun Ren, MD, Founder & CEO, Newsummit Biopharma

PANELISTS:

- Edward Hu, Chief Operating Officer & Chief Financial Officer, WuXi AppTec
- Weishi Li, PhD, JD, Partner, Covington & Burling
- Yuelei Shen, PhD, President & CEO, Biocytogen
- Dan Zhang, MD, Chairman & CEO, Fountain Medical Development

THURSDAY, OCTOBER 25, 2012
2:00 PM–3:25 PM
FUNCTION ROOM 2

Recommended for All Attendees

Globalizing Traditional Chinese Medicines

China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. With Western pharmas beginning to show an appetite for these treatments, many in-licensing and co-development opportunities exist. How can Western companies incorporate TCM into their portfolios and what regulations govern these products in China and the West? What pharmaceutical and clinical research processes can companies pursue to further TCM and turn out global, innovative products? Biopharma executives from both China and the West will share their TCM strategies and current projects.

MODERATOR:

- Helen Chen, Director & Partner, L.E.K. Consulting

PANELISTS:

- Henry Sun, President & CEO, Tasly Pharmaceuticals, Inc.
- Xun Zhang, PhD, Vice President & Head of Innovative TCM Performance Discovery Unit, GlaxoSmithKline
- Jian-ping Zuo, PhD, Professor and Director of Department of Pharmacology, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences

2012 年 10 月 25 日，星期四
14:00-15:25
功能厅 1

推荐所有与会者参与

发展趋势（第 2 部分）—中国研发结构的新模式

凭借政府推动生物技术领域创新的坚定承诺，近几年在中国涌现出了众多新的研发结构。研发型医药企业公司已经开始突破其传统的服务空间，纷纷推出自己的药物 研发平台，同时国内的学术与产业合作也在继续蓬勃发展。中国的生物技术公司也正在寻求接近他们的下一个合作伙伴，以促进药物研发流程的创新。专家小组将探 讨中国对生物技术创新的投入，为中国企业的研发结构带来了哪些新的模式。

主持人:

- 任军，创始人兼总裁，上海新生源集团

专家组成员:

- 胡正国，首席营运官兼财务总监，无锡药明康德公司
- 李唯实，合伙人，科文顿北京办公室
- 沈月雷博士，总裁， 北京百奥赛图基因生物技术有限公司
- 张丹，总裁，方恩医药

2012 年 10 月 25 日，星期四
14:00-15:25
功能厅 2

推荐所有与会者参与

传统中医药走向世界

几个世纪以来，中药一直在中国广泛使用，并且在中国医疗行业占据举足轻重的地位。现在，西方制药公司也开始涉足这一传统行业，希望分得一杯羹，现已出现多 个授权和联合开发项目。西方企业如何将中药整合到自己的产品组合中，中西方的哪些监管条例适用于这些药品？企业可以采取哪些制药和临床研发工艺来加工中药，使其成为广销全球的创新药物？中国和西方生物制药企业的高管们将就中药战略和当前的项目发表自己的看法。

主持人:

- 陈玮，负责人兼合作伙伴，艾意凯咨询公司

专家组成员:

- 孙鹤，总裁兼首席执行官，天津天士力制药公司
- Zhang Xun，副总裁及中医药研发部负责人，葛兰素史克
- 左建平博士，药理学教研室教授、主任，中国科学院上海药物研究所（SIMM）

Presenting Companies

Current as of Thursday, October 18, 2012

Please see final daily schedules posted in the corridors.

Presentations times and room locations can be found on the Program Grid at the BIO One-on-One Partnering Desk.

Company	Country
ACCB Biotech Ltd.	China
AstraZeneca	United States
BeiGene Ltd.	China
BioCrea	Germany
Chengdu Sen Nuo Wei Biotechnology Co., Ltd.	China
Debiopharm Group	Switzerland
Eddingpharm	China
Fountain Biopharma	Taiwan
Genentech	United States
GlaxoSmithKline	United States
Golden Biotechnology Corp.	Taiwan
Guangzhou International Biotech Island	China
HitGen Ltd.	China
Hua Medicine	China
Luqa Pharmaceuticals	China
MedGenesis Therapeutix	Canada
Metabolic Solutions Development Co.	United States
Pharmaessentia Corp.	Taiwan
Roche	United States
Sanofi	Switzerland
SciClone Pharmaceuticals	United States
SK Biopharmaceuticals	Korea
Spectrum Pharmaceuticals	United States
uniQure	The Netherlands

推介公司

截至2012年10月18日（星期四）

企业推介最终日程安排请见张贴在走廊上的通告。

请到BIO一对一合作伙伴服务台领取推介时间及地点安排表

企业	国家
北京雅康博生物科技有限公司	中国
阿斯利康	美国
百济神州生物技术有限公司	中国
BioCrea	德国
都森诺威生物科技有限公司	中国
Debiopharm Group	瑞士
亿腾医药（中国）有限公司	中国
泉盛生物科技股份有限公司	台湾
美国基因泰克公司	美国
葛兰素史克	美国
国鼎生物科技	台湾
广州国际生物岛	中国
成都先导药物开发有限公司	中国
华医药	中国
Luqa Pharmaceuticals	中国
MedGenesis Therapeutix	加拿大
Metabolic Solutions Development Co.	美国
药华医药股份有限公司	台湾
罗氏	美国
赛诺菲	瑞士
美国赛生药业公司	美国
SK生物制药公司	韩国
Spectrum Pharmaceuticals	美国
uniQure	荷兰

EXHIBITORS

Adroit People.....*Booth 302*

Adroit People is a key partner to the life science industry. We identify and connect executive talent and tomorrow's leaders with opportunities at every stage of the product development and commercialisation process.

BioCentury.....*Booth 104*

Biogen Idec.....*Booth 309*

Biogen Idec is the world's oldest independent biotechnology company, with more than US$5 billion in revenues. Biogen Idec's pipeline includes innovations in hematology, neurology and immunology.

Bionovo.....*Booth 102*

BioTest.....*Booth 200*

BioTest is dedicated to pre-clinical R&D (diabetes, neurology, cardiology, vaccines), preclinical and toxicological assessment (GLP-compliant) of pharmaceutical, biological, medical devices and the development of animal models of selected human diseases.

BioVendor.....*Booth 204*

BioVendor – Laboratorní medicína a.s., through its three divisions, produces and distributes medical equipment and medical research products for both the Czech Republic and international markets. Research & Diagnostic Divison of BioVendor - Laboratorni medicina a.s. is focusing on the discovery, development and marketing of innovative ELISA immunodiagnostic kits and related monoclonal and polyclonal antibodies and recombinant and native proteins. Our products are used in research and clinical labs of more than 60 countries including such demanding and competitive markets as the USA, EU countries and Japan.

CzechBio.....*Booth 101*

CzechBio is the national platform of Czech biotechnology industry. The association is comprised of 36members and its major focus is on design and production of recombinant proteins, antibodies and CRO services.

Czech Trade.....*Booth 105*

The Czech Trade agency is an official contact partner for those foreign companies looking for qualified Czech-based suppliers of products, providers of services or investors.

Fluor.....*Booth 300*

Fluor is the leading contractor of life sciences projects worldwide specializing in design-build-validate integration. Our Life Sciences business line has been serving the pharmaceutical and biotech industry for more than 40 years.

Hong Kong Science and Technology Parks Corporation.....*Booth 100*

HKSTPC provides state-of-the-art facilities and support services to biotech companies. HKSTPC, with its extensive connections, facilitates Chinese companies' entry into the global market.

Joinn Laboratories.....*Booth 400*

展商名单

Adroit People *302展位*

Adroit People 是生命科学行业一个主要合作伙伴，致力于识别并连接培养对象的发展需求，在新产品开发及商业化的各个阶段，为生物行业优秀的管理人才与未来的领导者提供机遇。

BioCentury *104展位*

百健艾迪 *309展位*

百健艾迪 （Biogen Idec） 作为世界上历史最为悠久的一家独立生物技术公司，营收超过50亿美元。公司业务线涵盖血液、神经及免疫学领域的研发与创新。

北京博诺威医药科技发展有限公司 *102展位*

BioTest *200展位*

BioTest 是一家专注于临床前研发（糖尿病、神经学、心脏学及疫苗）、生物制药与医疗器械临床前与毒理学评定（GLP标准）、以及特定人类疾病动物模型研发的领先公司。

BioVendor *204展位*

BioVendor – Laboratorní medicína a.s.是一家拥有三个业务部门,同时为捷克与国际市场提供医疗设备及医疗研究产品的公司。其研究与诊断部专注于创新型ELISA免疫诊断工具及相关单克隆与多克隆抗体、重组体及天然蛋白的发现、开发与营销。BioVendor的产品遍布世界范围内60多个国家与地区的临床实验室，其中包括美国、欧盟及日本等标准严格且极具竞争力的地区。

CzechBio *101展位*

CzechBio 是捷克共和国国家级的生物技术产业平台。该协会包含36名成员，主要专注于重组蛋白与抗体的研发、生产以及CRO服务。

捷克贸促会 *105展位*

捷克贸易局 （The Czech Trade agency）的主要目的是促进捷克与外国公司之间的国际贸易与合作。 捷克贸易局为捷克出口商进入国外市场提供专业的信息、支持及咨询服务，同时也是国外贸易商赴捷克寻求当地商业伙伴的“牵线搭桥人”。

福陆 *300展位*

福陆公司作为全球领先的生命科学工程承包商，为全球客户提供专业的设计、建造、厂房维护及项目管理等整体服务。其生命科学业务线具有服务于生物技术与制药产业超过40年的专业经验。

香港科技园公司 *100展位*

香港科技园致力于为生物科技企业提供高水准的设施与服务支持。公司以其广泛的资源及关系网络，为中国企业进入全球市场提供强有力的支持。

北京昭衍新药研究中心有限公司 *400展位*

EXHIBITORS

Marks & Clerk..... *Booth 201*

125 year-old UK-based intellectual property firm with 18 worldwide offices, 5 of which are in Asia: Beijing, Hong Kong, Kuala Lumpur, Melbourne, and Singapore.

Pardam LTD..... *Booth 103*

Pardam LTD is a producer of high quality inorganic and organic nanofiber materials and products on an industrial scale. Those products are globally distributed by Kertak Nanotechnology LTD. Ceramic nanofibers can be used in many applications such as catalyst, energy harvesting or composite materials. Whereas organic nanofiberous membranes can be used for water or air purification.

Pharmaceutical Biotechnology..... *Booth 202*

Pharmaceutical Biotechnology is a young dynamic company that focuses on the development and implementation of new biotech projects with high market potential. We have introduced to the market a new generation of female sanitary pads with the content of stabilized probiotic cultures. Pharmaceutical Biotechnology has developed new generation of patent probiotic - BIOFILM PROBIOTIC. A unique kind of technology is used when producing this product. This is the only product of its kind on the market.

Shamrock Structures..... *Booth 304*

Shamrock Structures is a protein crystallography research services company which provides fragment-based lead discovery, crystallization, co-crystallization, x-ray data collection, three dimensional structure determination and chemical synthesis.

Shook, Hardy & Bacon L.L.P..... *Booth 305*

Shook, Hardy & Bacon is an international law firm focused on litigation and patent prosecution. It has one of the largest practices in the world dedicated to serving clients in the pharmaceutical and biotechnology sectors. Partner Thomas Moga co-chairs the firm's Biotechnology and Life Sciences practice and has advised clients on international patent issues for more than two decades.

Sphere Fluidics Limited..... *Booth 205*

Sphere Fluidics has developed unique products for single cell analysis and characterisation and provides research and development services in this area. This enabling technology provides significant benefits for biologic discovery.

UPS..... *Booth 406*

UPS is a global leader in logistics. The reliable, compliant way in which we choreograph logistics for our healthcare partners has made us an industry leader. Headquartered in Atlanta, UPS serves more than 220 countries and territories worldwide.

US Commercial Service in China..... *Booth 307*

The US Commercial Service in China offers valuable assistance to American businesses exporting goods and services to China. Our office is part of a global network of trade specialists dedicated to assisting US commercial interests worldwide.

WuXi AppTec Co., Ltd...... *Booth 301*

A pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and United States offering services from discovery to commercialization that shorten time and lower the cost of R&D.

展商名单

麦仕奇 201展位

麦仕奇作为一家具有125年历史的知识产权公司，总部坐落于英国，并且在全球范围内拥有18家办事处。其在亚洲的5家办事机构分别设立于北京、香港、吉隆坡、墨尔本、以及新加坡。

Pardam有限责任公司 103展位

Pardam是一家提供高品质有机与无机纳米纤维材料及制品的专业化工业生产厂商。其产品由Kertak Nanotechnology公司在全球范围内进行销售。公司的陶瓷纳米纤维产品在催化剂、能量采集、复合材料等方面用途广泛，而有机纳米纤维膜则能够应用于空气与水的净化当中。

Pharmaceutical Biotechnology 202展位

Pharmaceutical Biotechnology作为一家年轻且充满活力的企业，专注于具有市场前景的新型生物技术项目的开发与实施。公司目前已经向市场成功推出了一款具有稳定性益生菌成分的新型女性卫生巾。此外，Pharmaceutical Biotechnology还研发出新一代益生菌专利产品——BIOFILM PROBIOTIC。该产品采用Pharmaceutical Biotechnology独特技术生成，是目前市场上唯一的此类产品。

Shamrock Structures 有限公司 307展位

Shamrock Structures是一家专注于蛋白质晶体学研究的公司。公司提供的研究与服务包含基于片段的先导化合物发现（Fragment-based Lead Discovery）、结晶、共结晶、X射线数据收集、三维结构测定及化学合成等。

Shook, Hardy & Bacon 律师事务所 305展位

Shook, Hardy & Bacon是一家专注于诉讼与专利申请的国际化律师事务所。其面向生物技术与制药行业的事业部作为世界上最大的同类事业部之一，致力于为生物产业的客户提供卓越的服务。公司由合伙人Thomas Moga主导其生物科技与生命科学业务，而他在国际专利领域则具有超过20年的客户服务与咨询经验。

Sphere Fluidics有限公司 205展位

Sphere Fluidics公司为单细胞分析及其特性描述提供独特的产品与研发服务。其先进的技术为生物学研发提供了强有力的支持与工具。

联合包裹速递服务公司 406展位

UPS作为全球领先的物流服务提供商，以其可靠、标准的服务方式为医疗保健领域的合作伙伴量身定制高水准的物流解决方案。 UPS的总部设在美国亚特兰大，服务范围涵盖全球220多个国家与地区。

广西南宁灵康赛诺科生物科技有限公司 203展位

广西南宁灵康赛诺科生物科技有限公司（Wincon）作为一家通过AAALAC认证的研发外包公司，致力于为药物发展、细胞与基因治疗以及医疗设备发展提供非人灵长类服务。

美国驻华商务处 307展位

美国驻华使领馆商务处是美国商务部全球网络的重要组成部分，帮助美国企业来华寻找合作伙伴，促进美国产品和服务的出口。

药明康德新药开发有限公司 301展位

药明康德新药开发有限公司（WuXi AppTec）于2000年12月成立，是全球领先的制药、生物技术以及医疗器械研发外包服务公司，在中美两国均有运营实体。药明康德向全球制药公司、生物技术公司以及医疗器械公司提供一系列全方位的实验室研发、研究生产服务，服务范围贯穿从药物发现到推向市场的全过程。

CONFERENCE FLOOR PLAN



会场平面图


会场平面图 3层
专题研讨会
企业推介
自动扶梯
主题演讲
大上海宴会厅1号
签到处
一对一合作会谈问询总台
同声传译耳机领取
上/下午间休
闭幕酒会
一对一合作会谈及展会
大上海宴会厅2&3号
自动扶梯
早餐及社交午餐
浦东宴会厅

MODERATORS

WEDNESDAY, OCTOBER 24, 8:30–9:55AM

Globalization of Chinese Companies

Luo Xielong – President, Renhe Group & Executive Vice President, CPEA

Mr. Luo Xielong has been President of Renhe Group since 2010. He previously served as Deputy General Manager of Beijing Pharmaceutical Co., Ltd., Central Research Institute, President of Beijing Pharmaceutical Co., Ltd., and Chairman of Chinese Medicine Research and Development Center from 2003 to 2012; GM, Peking University Health Science Center Yikang Technology Corporation and GM, Scrianen Pharmaceutical from 1994 to 2002; Deputy General Manager, Hong Kong Yizhou Group and GM, Shenzhen Yizhou High-tech Industry Co., Ltd. from 1990 to 1993; Division Chief, Division of Medical Service, Health Department, Hangzhou and Deputy Director, Zhejiang Administration Committee of Hospitals from 1983 to 1990.

In addition, he is a consultant to the Chinese Medicine Department, UNIDO, Vice President, CABA, Vice President, CJMST, Executive Vice President, CPEA, Director, Professional Committee of China Pharmaceutical Enterprise Internationalization, Director, Preparatory Committee of China Pharmaceutical Enterprise Innovative Preparation Industry Alliance, Executive Vice Chairman, China Biopharm CRO Alliance, Executive Vice Director, Cosmeceuticals Committee, China OTC Association, President and Honorary President, Industry & Commerce Beautyculture & Cosmetics Chamber, President, Beijing Zhongguancun Enterprise Association Of Biotech.& Pharma, Consultant for Industry Plan and Investment of China Medical City Taizhou, Group Leader, Biopharm 12th Five-year Plan Development Plan Research Group, Zhejiang Development and Reform Committee, Management and Investment Consultant, Hangzhou Biological Industrial & National High-tech Industrial Zone. Besides above mentioned posts, Mr. Luo has also served as an independent director and management consultant for dozens of domestic and overseas companies.

Mr. Luo graduated from Harbin Medical University and holds an EMBA both from Sino-European International Management Institute (Project and Investment Management) and Peking University Experimental Testing Center for Economics and Management (Business Management).

Biopharma Strategy 101: Biopharma's China Business Plan

Rajesh Parekh – Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company

Rajesh (Raj) is the leader of McKinsey's Asia Pharmaceuticals and Medical Products Practice. He joined McKinsey's Chicago office in 1996 and since 2005 has worked in our Shanghai office. He serves clients across the pharmaceutical and medical device and equipment sectors on their Asian businesses, with a focus on China, India, and Japan. Raj's work spans a range of areas including growth strategy, sales & marketing and R&D. Raj led McKinsey's internal knowledge effort to assess the impact of the recent healthcare reform on the medical device and equipment industry in China.

Recent medical device and equipment experience includes working with a global implantable medical device leader to develop breakthrough growth strategies for China and India; helping a leading hospital infusion equipment player assess attractiveness of the "value segment" in China and develop product and customer segmentation approach to capture the most attractive opportunities; and working with a leading medical device company to develop organization blueprint to manage the emerging market set of countries.

Raj holds a PhD in Chemical Engineering from University of Illinois at Urbana-Champaign and a BS in Chemical Engineering from University of California at San Diego.

座谈会主持人

10 月 24 日，星期三，上午 8:30-9:55

中国企业走向世界

骆燮龙－仁和集团总裁和 CPEA 执行副总裁

自 2010 年以来，骆燮龙先生就一直担任仁和集团的总裁。此前，他曾担任北京医药股份有限公司副总经理，中央研究所，北京制药有限公司总裁，中国医药研究开发中心主席（2003 至 2012）；北京大学健康科学中心益康科技公司总经理；Scrianen 药业公司总经理（1994 至 2002）；香港亿洲集团副总经理和深圳亿洲高新技术产业有限公司总经理（1990 至 1993）；杭州卫生局医疗服务部处长，以及浙江省医院管理委员会副主任（1983 至 1990）。

此外，他还是中国医学部顾问，联合国工业发展组织顾问，CABA 副总裁，CJMST 副总裁，CPEA 执行副总裁，中国医药企业国际化专业委员会主任，中国医药企业创新制备产业联盟筹备委员会主任，中国生物医药 CRO 联盟常务副会长，中国非处方药协会药妆品委员会常务副主任，美容及化妆品工商会主席和名誉主席，北京中关村的生物技术和制药企业协会会长，泰州中国医药城产业规划和投资顾问，生物医药十二五规划发展规划研究组组长，浙江省发展和改革委员会，杭州生物产业国家高新技术产业开发区管理和投资顾问。除了上面提到的职位，骆先生还担任着数十家国内及海外公司的独立董事和执行顾问。

骆先生毕业于哈尔滨医科大学，持有中欧国际管理学院（项目和投资管理）和北京大学经济管理实验教学中心（工商管理）的高级工商管理硕士（EMBA）证书。

生物制药战略 101：生物制药巨头的在华业务计划

潘睿杰 － 麦肯锡公司亚洲制药和医药产品部主管

潘睿杰先生是麦肯锡公司亚洲制药和医药产品部负责人潘睿杰于 1996 年加入麦肯锡芝加哥分公司。他于 2005 年调任上海分公司，并一直供职于此。他的客户包括多家亚洲制药、医疗设备企业，并主要服务于中国、印度和日本企业。他的工作职责横跨多个领域，包括制定公 司发展战略、销售和营销，以及研发工作。他还同时率领麦肯锡内部智囊团，积极研究中国政府医改政策对医疗设备行业的影响。

近期医疗设备从业经验包括：与一家全球可移植医疗设备领先企业合作，制定针对中国和印度的突破性增长策略；帮助一家领先的医院输液设备制造商评估在中国 “高利润细分市场”的商机，并制定产品和客户细分方法，以把握获利最大的机会；帮助一家知名医疗设备公司撰写企业蓝皮书，以管理该公司在多个国家的新兴市场业务。

潘睿杰拥有伊利诺斯大学香槟分校化学工程博士学位，以及圣地亚哥加州大学化学工程学士学位。

MODERATORS

WEDNESDAY, OCTOBER 24, 1:30–2:55PM

Achieving Success via Innovation in Biosimilars

Alan Morrison – Vice President, Regulatory Affairs, Amgen

Alan Morrison, Vice President, leads Amgen's International Regulatory Affairs & Safety functions of approx. 300 staff both in the UK and across more than 30 local affiliate offices worldwide. As well as part of the Global Regulatory Affairs & Safety leadership, Alan is also key member of Amgen's cross-functional International Management Committee, which sets and guides the International business overall strategic direction.

Alan joined Amgen in 2004, having previously held a number of regulatory affairs and safety positions at a number of companies including Baxter Bioscience.

Alan is currently Chairman of the BioIndustry Association's Regulatory Affairs Group and acting on a number of trade association committees related to biotechnology / biopharmaceuticals.

Small Companies Thinking Big: China Tactical Strategies

Jimmy Zhang – Greater China Lead, Licensing, Acquisitions & External Research, Worldwide Licensing & Acquisitions, Merck/MSD

Dr. Jimmy Zhang is Greater China Lead, Licensing, Acquisitions & External Research at Merck & Co., and a member of Leadership Team of MSD China R&D. He's responsible for Merck's licensing, acquisitions, research collaboration, alliance/partnership management and venture capital investments in Greater China.

Before joining Merck, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT. Jimmy is responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China.

Jimmy was previously a consultant at McKinsey & Company traveling and working in China, US and Germany, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).

Jimmy received his BS in biochemistry from Nanjing University, and PhD in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.

Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. He's a founding member and the current Chairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai. Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on business development and doing business between US and China. He is often quoted in both US and Chinese news media.

座谈会主持人

10 月 24 日，星期三，下午 13:30-14:55

通过生物仿制药创新项目取得成功

Alan Morrison －副总裁，安进

Alan Morrison先生，副总裁，负责安进公司的药物法规及安全。下属大约300名员工，分别位于伦敦及世界各地30多个分支机构。

作为全球注册事务和安全部的领导之外，Alan还是Amgen公司具跨部门协调功能的国际管理委员会的重要成员，从总决策层面设定和指导国际业务的发展方向。

Alan于2004年加入Amgen公司，之前在百特公司等多家企业任职于注册事务和安全领域。

Alan 目前是BIO协会下注册事务组的主席，同时也是多家生物技术/生物制药协会的成员。

小企业大思想：中国战术策略

Jimmy Zhang － 默克制药公司全球授权与收购大中国区负责人

Jimmy Zhang博士是默克公司授权、并购与外部研究事业大中华区的总负责人，同时也是默沙东中国研发中心核心领导团队的成员之一，负责默克公司在大中华区的授权许可与并购、研发合作、联盟与合伙、及风险投资项目。

在加盟默克公司之前，Jimmy曾在Synergenics有限责任公司担任高级副总裁。Synergenics公司由作为生物产业先锋与奠基人之一的Bill Rutter博士创办，专注于风险投资与专业服务，对处于药物研发、疫苗、诊断及医疗保健信息技术早期发展阶段的公司进行管理与投资。Jimmy曾负责Synergenics及其投资公司的商务拓展与营运事务，及其在中国的业务。

Jimmy早先还曾在麦肯锡咨询公司担任咨询顾问，奔走于中、美、德三国之间。还曾是Morrison & Foerster律师事务所帕洛阿尔托办公室的注册专利代理人、及Chiron公司（现属于诺华公司）的项目经理。

Jimmy拥有南京理工大学生物化学学士学位，并从美国得克萨斯大学达拉斯西南医学中心获得了生物医学博士学位。读博期间，他曾与两位诺贝尔奖得主进行密切合作。在麻省理工学院斯隆管理学院攻读MBA硕士期间，Jimmy还曾当选为麻省理工学院研究生会财务主管。另外，他还曾是麻省理工学院第12届5万美元创业大赛的决赛选手。

Jimmy曾在《Cell》、《Nature》、《Neuron》以及《JBC》等知名学术刊物上发表文章，并拥有多项专利。他还是中国生命科学领域知名的非盈利组织——BayHelix集团的创始成员、现任主席及董事。此外，Jimmy也是ChinaSF与Bay Area Council中国委员会的战略顾问，以及上海同济大学客座教授。他经常受邀出席生物制药与高新技术行业会议，就中美商务拓展与合作发表演讲或参与研讨。其观点常常被中美新闻媒体所引述。

MODERATORS

WEDNESDAY, OCTOBER 24, 3:30–4:55PM

Comparative Legal Systems—US, China & Beyond

Moderator TBD

Trends in Cancer Research and Oncology Treatment Development in China

Richard Yeh – Head, China Healthcare Research, Citi Investment Research

Richard Yeh is the head of China healthcare research at the Citi Investment Research in Hong Kong, and he was ranked No.2 in both the 2012 and 2011 All-China Institutional Investor Survey, and #3 in All-Asia Institutional Investor Survey. Richard joined the Hong Kong-based China research team from Citi's New York office, where he was a member of the US large-cap biotechnology/healthcare team that was ranked No.4 in both 2008 and 2009 All-America Institutional Investor Survey. Before joining Wall Street, Richard gained extensive industry experience working at the global strategic marketing group at Wyeth Pharmaceuticals and conducted drug discovery research at Amgen.

座谈会主持人

10 月 24 日，星期三，下午 15:30-16:55

比较美国，中国及它国的法律体系

待定

中国的癌症研究和肿瘤治疗发展趋势

Richard Yeh - 亚太地区医疗主管,花旗投资调研

作为香港花旗投资研究中国医疗保健研究事业的首要负责人，曾在2011与2012年的中国机构投资者调查中名列第二，全亚洲机构投资者调查中名列第三。在加入香港的中国研究团队之前，Richard Yeh曾是花旗集团纽约办公室生物技术与医疗保健高市值研究团队的成员。该团队在2008 及2009年度的全美机构投资者调查中排名第四。在加入华尔街以前，Richard Yeh在惠氏制药负责全球战略营销事务，并曾在安进从事药物研发工作。这些工作经历使他积累了资深的行业经验。

MODERATORS

WEDNESDAY, OCTOBER 24, 4:30–5:25 PM

Industry Discussion: Building a World-Class Innovative Biologics Industry in China

Joseph Damond – Senior Vice President, International Affairs, Biotechnology Industry Organization (BIO)

As Senior Vice President for International Affairs at the Biotechnology Industry Organization (BIO), Mr. Damond is responsible for developing and implementing the industry association's program of international advocacy and outreach, including the areas of trade policy and foreign government relations.

Prior to taking his position at BIO, Mr. Damond was Vice President for International Government Relations in Pfizer's Washington Office from 2006-2011. In that capacity he was responsible for managing and coordinating Pfizer's international trade issues with the Administration and Congress.

Prior to his appointment at Pfizer in 2006, Mr. Damond was with the Pharmaceutical Research and Manufacturers of America (PhRMA) for five years. As PhRMA's Deputy Vice President for International Affairs, he was responsible for managing PhRMA's programs with respect to market access barriers that affect the research-based pharmaceutical industry, as well as managing PhRMA's Asia and Japan programs.

Before coming to PhRMA, Mr. Damond spent 12 years as a trade negotiator at the Office of the United States Trade Representative, where his last assignment, from 1999-2001, was as Deputy Assistant US Trade Representative for Asia and Pacific/APEC Affairs. During this time, he was also chief negotiator of the historic US-Vietnam Bilateral Trade agreement, completed in July 2000. Prior to his time at USTR, Mr. Damond also spent four years at the US Commerce Department, working on bilateral and multilateral trade negotiations.

Mr. Damond received his Master's degree from Princeton University's Woodrow Wilson School of Public and International Affairs in 1985, and his undergraduate degree magna cum laude from Georgetown University, School of Foreign Service, in 1983.

Trends in Investment and Cross-Border Development

Sun Wansong, PhD – Director of Investment Promotion, Ministry of Commerce, People's Republic of China

Dr. Sun Wansong serves as Director of the Project Operation Department of the China Investment Promotion Agency at the Ministry of Commerce. He holds a Doctoral degree in Management, and finished his post-doctoral research at Tsinghua University. Dr. Sun's research has focused on the innovation and development of industrial parks. He has published four books, including Self-Innovation and Core Competence in High-Tech Zones, and over 20 academic papers in national top-level journals and international conferences. Dr. Sun has won several provincial and national Social Science Outstanding Achievement Awards and Technological Progress Awards.

座谈会主持人

10 月 24 日，星期三，下午 16:30-17:25

行业讨论：打造世界一流的中国创新型生物制品企业

Joseph Damond - 国际事务部高级副总裁，全球生物技术产业组织（BIO）

作为全球生物技术产业组织（BIO）主导国际事务的高级副总裁，Damond 先生的职责包括制定与实施行业协会的项目和大型活动的国际宣传及推广方案，以及对外国政界关系与贸易政策的处理。

在加盟BIO以前，Damond 先生曾在2006年至2011年期间担任辉瑞公司华盛顿办公室国际政府关系副总裁，管理并协调辉瑞在国际贸易方面与政府及国会的关系。

早先于2006年加入辉瑞，Damond先生还曾在美国药物研究与制造协会（PhRMA）任职五年。 作为 PhRMA 国际事务副总裁，Damond 先生负责管理与制药产业市场准入壁垒相关的项目，并主导 PhRMA 的日本与亚洲项目。

Damond 先生还曾在PhRMA之前担任美国贸易代表办公室贸易谈判代表12年，并在1999年至2001年的最后任职期间成为办公室针对亚洲及太平洋地区/亚太经济合作组织事务的办公室助理主任。 在此期间，他是具有历史性意义的美越双边贸易协议的首席谈判代表，使协议在2000年7月最终达成。 Damond 先生还曾在美国商务部工作四年，主要负责双边及多边贸易的谈判。

Damond 先生于1985年获得美国普林斯顿大学伍德罗·威尔逊公共与国际事务学院硕士学位，并于1983年以优等成绩获得美国乔治敦大学外交学院本科学位。

投资及跨国发展的趋势

孙万松 - 商务部投资促进事务局中心项目运营部主任

孙万松，男，管理学博士，清华大学公共管理学院博士后，商务部投资促进局项目部主任。一直从事园区经济和创新的研究，在《中国软科学》、《管理现代化》等刊物发表论文 20 多篇，出版《高 新区自主创新与核心竞争力》、《园区经济与核心竞争力》等专著 4 本，曾多次获得省部级优秀社会科学成果奖和科技进步奖。

MODERATORS

THURSDAY, OCTOBER 25, 8:30–9:55AM

Leadership Models in Translating Innovative Sciences

Li Qing – Director, Medicines Science and Technology Development Center, Ministry of Health

Mr. Li Qing's is responsible for, compiling the Development Plan for Medical Science and Technology during the "Twelfth-Five Year Plan" period; assisting and organizing to implement two national key science and technology programs, i.e. "New Drugs Innovation and Development" and "Major Infectious Diseases"; initiating the special scientific research programs for medical health industry in 2010 and 2011; organizing to disseminate the applicable health technologies; taking charge of the management and coordination of the remote continuing education for health industry; assuming the work of the Health Industry Teaching Material Management Office and providing the technical service and agency service concerning medical health industry.

Mr. Li was chief of the Industry Development Department of China National Center for Biotechnology between 2007 and 2010, associate research fellow of the Policy Coordination Department of China National Center for Biotechnology between 2002 and 2007, appointed assistant to director of Tianjin Municipal Science and Technology Commission between November 2006 and June 2009, in charge of the preparatory work for establishing "National Bio-Medicine International Innovation Park" and "Tianjin International Joint Academy of Biotechnology and Medicine". Before this, he was assistant research fellow of the Gene and Cell Engineering Department of China Bioengineering Development Center.

Li Qing graduated from the Department of Biology of Nankai University, majoring in plant physiology and ecology.

Adapting to China's Changing Health Care System— Reimbursement, Health Care Reform & Affordability

George Baeder – Senior Vice President, Asia Pacific Consulting and China Commercial, Quintiles

George leads Quintiles Consulting Asia/Pacific and the firm's Commercial business in China, based in Shanghai. He has spent over 30 years in Asia working with leading Asian and Western firms to build profitable high-growth businesses in the region's most challenging and complex markets. He is widely considered to be a thought leader in the industry, having worked on the cutting edge of innovative approaches to market entry, R&D, access and new commercial models - helping clients take decisive moves ahead of competitors.

His life science consulting in began with as an advisor on the first pharma joint venture in China set up by an Astra-led consortium of five Swedish companies in Wuxi . Since then he has work with all of the leading Western biopharma firms both in China and across the Asian region. George combines strong strategy skills and analytics with an intensely practical focus on implementation.

Prior to joining Quintiles Consulting, George led the Monitor Group's Life Science practice in Asia for nine years. In the early part of his career, George built two professional services firms that he subsequently sold to leading global players in their respective fields. He then spent three years as an investment banker with working on Asian-focused life science transactions.

George was educated in Economics at Lafayette College and then studied China's economic development at Oakland University and Taiwan Normal University.

座谈会主持人

10 月 25 日，星期四，上午 8:30-9:55

创新型转化医学的领导层模式

李青 - 卫生部医药卫生科技发展研究中心主任

李青先生，主要负责编制医药卫生科技发展“十二五”规划；协助“重大新药创制”和“重大传染病”两个国家重大科技专项的组织实施；启动医药卫生行业科研专项2010和2011年项目；组织适宜卫生技术推广工作；负责卫生行业远程继续教育的管理和协调；承担卫生行业教材管理办公室相关工作以及开展医药卫生行业的技术和产业中介服务。

李先生在2007到2010年间，任中国生物技术发展中心产业发展处处长，在2002年到2007，在中国生物技术发展中心政策协调处处长担任副研究员，并于2006.11到2009年6月，挂职天津市科学技术委员会主任助理，负责“国家生物医药国际创新园”和“天津国际生物医药联合研究院”的筹建。更早的时候，在中国生物工程开发中心基因与细胞工程处担任助理研究员。

李青毕业于天津南开大学生物系植物生理专业。

适应中国不断变化的医疗保健体系—医疗报销、医疗保健改革和负担能力

乔治·贝德 - 高级副总裁，昆泰咨询亚太区及昆泰商业中国业务

George是昆泰咨询亚太区以及昆泰商业中国业务的负责人。他在亚洲拥有超过30年的工作经验，曾协助多家亚洲及西方知名企业在环境复杂且极具挑战性的亚洲市场实现盈利、建立高增长业务。作为在业界受到广泛认可的思想领袖，George在市场进入、研发设置及新商业模式探索领域经验丰富，并且始终站在创造性解决问题的最前沿。他帮助客户果断决策，从而领先于竞争对手，把握先机。George的生命科学咨询职业生涯起始于担任由5家瑞典企业在无锡共同设立的合资企业的顾问。而这家公司则是中国制药业的第一家合资药企。自那时起，他就开始协助一些知名西方药企在中国与亚洲开展业务。他能够将战略性分析与实践结合，从而给出切实可行的计划并实施.

在加盟Quintiles咨询以前，George曾经领导摩立特集团亚洲生命科学事业长达9年。早先，他还曾创立了两家专业服务公司。而这两家公司随后则分别被出售给行业领先的国际名企。此后，他还曾作为一名投资银行家在亚洲生命科学投资交易领域工作三年。George曾在美国拉斐特学院学习经济，并在美国奥克兰大学及台湾师范大学研究中国经济发展。

MODERATORS

THURSDAY, OCTOBER 25, 12:30–1:55PM

Development Trends (Part 1)—New Models of Cross-Border R&D Structures

Steve Yang – Vice President, Head of R&D for Asia and Emerging Markets, AstraZeneca

Dr. Steve Yang is Vice President, Head of R&D for Asia and Emerging Markets at AstraZeneca. He is based in Shanghai, China and is responsible for developing, implementing and aligning the company's R&D strategy for Asia and Emerging Markets.

Prior to joining AstraZeneca, Dr. Yang was Vice President, Head of Asia R&D at Pfizer, where he was charged with establishing and expanding the company's research partnership network with academic institutions, biotechnology firms and Contract Research Organizations across Asia Pacific. He was also responsible for delivering a portfolio of preclinical and clinical stage projects targeting unmet medical needs of emerging markets. Prior to his leadership position in Asia, Dr. Yang was Executive Director and head of the company's global R&D strategic management group.

Before joining Pfizer Dr. Yang held a number of positions at IntraBiotics Pharmaceuticals, a US-based biotech company and also worked for Strategic Decisions Group (SDG), a management consulting firm for Fortune 100 companies.

Dr. Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders.

Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, USA. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University, USA.

Regulatory Review Process of New Medicines in China

Shaoyu Chen – Partner, Covington & Burling LLP

Shaoyu Chen is a member of the firm's Food and Drug practice group and the managing director of its China food and drug practice. Mr. Chen has over 10 years experience in food and drug law, including serving as assistant chief counsel at the United States Food and Drug Administration Office of Chief Counsel, as senior counsel at Amgen Inc., and as chief compliance counsel for GE Healthcare China. Mr. Chen represents pharmaceutical, biotechnology, medical device, food, dietary supplement, and cosmetic companies in matters before the China SFDA, the US FDA, and other government agencies. He regularly assists clients on legal and regulatory issues related to SFDA and FDA oversight, including those pertaining to preclinical research, clinical trial, marketing approval, advertising and promotion, manufacturing GMP, pharmacovigilance, import and export, and compliance with Foreign Corrupt Practices Act and China Anti-Unfair Competition Law.

座谈会主持人

10 月 25 日，星期四，下午 12:30-13:55

发展趋势（第 1 部分）—跨国研发结构的新模式

杨青 - 亚洲及新兴市场研发总裁，全球研发副总裁
阿斯利康全球研发

杨青先生是阿斯利康公司全球研发的亚洲及新兴市场研发总裁。他目前在中国上海工作，主要工作包括制定、实施和调整公司在亚洲及新兴市场的研发战略。

在加入阿斯利康之前，他曾担任辉瑞制药公司亚洲副总裁，研发负责人，负责与亚太地区研究所、生物技术公司和研发外包公司建立和扩大合作伙伴关系。他的职责 还包括，针对新兴市场未得到满足的医疗需求，发展一系列临床前和临床阶段的研发项目。在成为亚洲地区负责人前，杨青先生曾是辉瑞制药公司的执行董事，主管 公司全球研发部战略管理小组。

在加入辉瑞前，他曾在一家美国生物技术公司 IntraBiotics Pharmaceuticals 身兼数职，同时还曾供职于美国战略决策集团 （Strategic Decisions Group），该集团是一家管理咨询公司，主要服务于世界财富 100 强的公司。杨青先生是百华协会的创始人之一。百华协会是由多位生命科学领域的杰出华人商业领袖所组成的非盈利性组织。

杨青先生拥有美国加利福尼亚大学药物化学博士学位。他在复旦大学开始学习本科课程，在美国密西根理工大学取得生物学本科学位，并以优等生身份毕业。

中国新药监管审核流程

陈少羽 - 合伙人，科文顿·柏灵律师事务所

陈少羽律师是本所食品与药品业务团队成员,也是本所中国食品与药品法律团队的负责人。陈律师在食品与药品法律领域拥有十多年经验，曾任美国食品药品监督管理局的助理法律顾问、美国安健生物制药公司的高级法律顾问、以及通用电气（中国）医疗集团首席合规顾问。陈律师擅长协助制药、生物制品、医疗器械、食品、膳食补充剂、以及化妆品公司处理与中国药监局、美国药监局及其他政府部门有关的事宜。陈律师还经常协助客户处理与中国药监局、美国药监局监督有关的法律和监管事宜，包括临床前研究、临床试验、上市批准、市场推广、生产质量规范、安全监控及报告、进出口，以及《美国反海外腐败法》和《中国反不正当竞争法》合规等方面的问题。

MODERATORS

THURSDAY, OCTOBER 25, 2:00–3:25PM

Globalizing Traditional Chinese Medicines

Helen Chen – Director and Partner, Head of China Life Sciences, L.E.K. Consulting

Helen Chen is a director and partner of L.E.K. Consulting based in Shanghai. She is the co-head of the China office and a member of L.E.K.'s Global Leadership Team, the firm's governing committee. Helen has over 20 years of consulting and industry experience in the US and Asia, and has resided in China since 2000.

Helen is the head of L.E.K.'s China life sciences practice, with extensive case work and industry experience covering the full bio/pharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. She is on the Editorial Board of PharmAsia and on the Advisory Committee for BIO China. Helen is a sought after speaker and author on the opportunities and issues in the China healthcare and life sciences.

Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the US and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997, and was honored by Who's Who Among American Women from 1993 to 1995.

Helen received her AB cum laude in applied mathematics from Harvard University.

座谈会主持人

10 月 25 日，星期四，下午 14:00-15:25

传统中医药走向世界

陈玮 - 中国生命科学负责人，董事及合作伙伴
艾意凯咨询公司

陈玮是上海艾意凯咨询公司的董事和合作伙伴。她是中国办事处联席主管和艾意凯咨询公司全球领导团队及公司管理委员会成员。陈玮在美国和亚洲有超过 20 年的咨询和行业经验，从 2000 年起在中国居住。

陈玮是艾意凯咨询公司的中国生命科学业务负责人，拥有在整个生物/制药技术和医药科技价值链上从业的丰富案例和经验，从早期研究服务到后期市场的产品定位 和销售队伍效率，无所不包。她是亚洲医药编委会和 BIO 中国咨询委员会的成员。陈玮在探讨中国医疗保健和生命科学机遇和问题方面，是一位享有盛名的演讲专家和专题作者。

加入艾意凯咨询公司之前，陈玮在几家美国和中国的技术公司担任高级管理职务。她曾担任基因泰克公司的财务副总监和主持雅培公司的销售计划。从 1995 至 1997 年，她曾在药品管理科学协会董事会工作，并在 1993 至 1995 年间被收入“美国女性名人录”。

陈玮以优异成绩从哈佛大学取得了应用数学文学学士学位。

Notes